Early identification of neoadjuvant therapy non-response via multimodal immune-imaging biomarkers in breast cancer - Takeaways - MDSpire

Early identification of neoadjuvant therapy non-response via multimodal immune-imaging biomarkers in breast cancer

  • By

  • Xiangyuan Zhou

  • Xianming Huang

  • Lan Liu

  • Xiaoqin Cai

  • Han Li

  • Zhikang Sun

  • Zongqing Qiu

  • Jinxiu Zhong

  • Tenghua Yu

  • Qiao Zeng

  • June 10, 2026

  • 0 min

Share

  • 1

    A multimodal prediction model was developed to identify breast cancer patients unlikely to respond to neoadjuvant therapy (NAT).

  • 2

    The study included 112 patients, with 33.9% classified as non-responders based on Miller–Payne grades 1–3.

  • 3

    Key predictors in the model included HER2 status, Ki-67 index, tumor-infiltrating lymphocytes, and systemic inflammatory markers.

  • 4

    The multimodal model achieved an apparent AUC of 0.933, indicating strong predictive performance for NAT non-response.

  • 5

    External validation of the model is necessary due to the study's limited sample size and exploratory design.

Original Source(s)

Early identification of neoadjuvant therapy non-response via multimodal immune-imaging biomarkers in breast cancer

  • by Xiangyuan Zhou, Xianming Huang, Lan Liu, Xiaoqin Cai, Han Li, Zhikang Sun, Zongqing Qiu, Jinxiu Zhong, Tenghua Yu, Qiao Zeng

  • June 10, 2026

Related Content

Tertiary lymphoid structures in breast cancer: formation, immune functions and clinical implications

Evaluating the efficacy and safety of first-line immunotherapy for metastatic triple-negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials with a focus on PD-L1 expression

Optimizing outcomes with less than more: multi-institutional experience of fast-forward fractionation and the impact of dosimetric parameters on toxicity in breast cancer patients